Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1979 Sep;64(3):721–728. doi: 10.1172/JCI109515

Properdin factor D: effects on thrombin-induced platelet aggregation.

A E Davis 3rd, D M Kenney
PMCID: PMC372173  PMID: 468986

Abstract

Factor D, when preincubated with platelet suspensions, at concentrations as low as 1.2 micrograms/ml, inhibited thrombin-induced platelet aggregation. No inhibition of collagen or arachidonic acid-induced platelet aggregation was found. Inhibition occurred, but to a lesser extent, when thrombin and factor D were added to platelets at the same time. No inhibition occurred when factor D was added after thrombin. Thrombin was able to overcome inhibition by factor D by increasing its concentration. Diisopropyl-phosphorofluoridate-inactivated factor D also inhibited thrombin-induced platelet aggregation so that enzymatic activity of factor D was not required for inhibition. Factor D absorbed with hirudin coupled to Sepharose 6B showed no decrease in inhibitory capacity. 125I-Factor D bound to platelets in a manner suggesting an equilibrium reaction similar to thrombin. At low factor D input, binding was linear, whereas at higher input, binding began to approach saturation. Binding of 125I-labeled thrombin to platelets was inhibited by factor D. Analysis of these data show that factor D does not alter the total number of thrombin molecules which bind to the platelet surface at saturation. However, the dissociation constant for thrombin is altered from 2.78 to 6.90 nM in the presence of factor D (20 micrograms/ml). Factor D is thus a competitive inhibitor of thrombin binding, although the affinity of factor D for the platelet thrombin receptor is much less than that of thrombin. These phenomena occur at physiologic concentrations of factor D. Therefore, factor D may function in vivo as an inhibitor of platelet aggregation.

Full text

PDF
721

Images in this article

723Image
on p.723

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Rosen F. S. Genetic aspects of the complement system. Adv Immunol. 1971;14:251–290. doi: 10.1016/s0065-2776(08)60286-2. [DOI] [PubMed] [Google Scholar]
  2. Awdeh Z. L., Williamson A. R., Askonas B. A. Isoelectric focusing in polyacrylamide gel and its application to immunoglobulins. Nature. 1968 Jul 6;219(5149):66–67. doi: 10.1038/219066a0. [DOI] [PubMed] [Google Scholar]
  3. Bolton A. E., Hunter W. M. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J. 1973 Jul;133(3):529–539. doi: 10.1042/bj1330529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Breckenridge R. T., Rosenfeld S. I., Graff K. S., Leddy J. P. Hereditary C5 deficiency in man. III. Studies of hemostasis and platelet responses to zymosan. J Immunol. 1977 Jan;118(1):12–16. [PubMed] [Google Scholar]
  5. Davey M. G., Lüscher E. F. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature. 1967 Dec 2;216(5118):857–858. doi: 10.1038/216857a0. [DOI] [PubMed] [Google Scholar]
  6. Dixon R. H., Rosse W. F. Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets. J Clin Invest. 1977 Feb;59(2):360–368. doi: 10.1172/JCI108648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fearon D. T., Austen K. F., Ruddy S. Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med. 1974 Feb 1;139(2):355–366. doi: 10.1084/jem.139.2.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ganguly P., Sonnichsen W. J. Binding of thrombin to human platelets and its possible significance. Br J Haematol. 1976 Oct;34(2):291–301. doi: 10.1111/j.1365-2141.1976.tb00199.x. [DOI] [PubMed] [Google Scholar]
  9. Hunsicker L. G., Ruddy S., Austen K. F. Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol. 1973 Jan;110(1):128–138. [PubMed] [Google Scholar]
  10. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  11. Lages B., Scrutton M. C., Holmsen H. Studies on gel-filtered human platelets: isolation and characterization in a medium containing no added Ca2+, Mg2+, or K+. J Lab Clin Med. 1975 May;85(5):811–825. [PubMed] [Google Scholar]
  12. Lesavre P. H., Müller-Eberhard H. J. Mechanism of action of factor D of the alternative complement pathway. J Exp Med. 1978 Dec 1;148(6):1498–1509. doi: 10.1084/jem.148.6.1498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Martin A., Lachmann P. J., Halbwachs L., Hobart M. J. Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry. 1976 Apr;13(4):317–324. doi: 10.1016/0019-2791(76)90341-4. [DOI] [PubMed] [Google Scholar]
  14. Martin B. M., Feinman R. D., Detwiler T. C. Platelet stimulation by thrombin and other proteases. Biochemistry. 1975 Mar 25;14(6):1308–1314. doi: 10.1021/bi00677a032. [DOI] [PubMed] [Google Scholar]
  15. Martin B. M., Wasiewski W. W., Fenton J. W., 2nd, Detwiler T. C. Equilibrium binding of thrombin to platelets. Biochemistry. 1976 Nov 2;15(22):4886–4893. doi: 10.1021/bi00667a021. [DOI] [PubMed] [Google Scholar]
  16. Martin S. E., Breckenridge R. T., Rosenfeld S. I., Leddy J. P. Responses of human platelets to immunologic stimuli: independent roles for complement and IgG in zymosan activation. J Immunol. 1978 Jan;120(1):9–14. [PubMed] [Google Scholar]
  17. Müller-Eberhard H. J., Götze O. C3 proactivator convertase and its mode of action. J Exp Med. 1972 Apr 1;135(4):1003–1008. doi: 10.1084/jem.135.4.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Parikh I., March S., Cuatercasas P. Topics in the methodology of substitution reactions with agarose. Methods Enzymol. 1974;34:77–102. doi: 10.1016/s0076-6879(74)34009-8. [DOI] [PubMed] [Google Scholar]
  19. Pfueller S. L., Lüscher E. F. Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. I. Complement-dependent and complement-independent reactions. J Immunol. 1974 Mar;112(3):1201–1210. [PubMed] [Google Scholar]
  20. Pfueller S. L., Lüscher E. F. Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. II. The effects of zymosan. J Immunol. 1974 Mar;112(3):1211–1218. [PubMed] [Google Scholar]
  21. Polley M. J., Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med. 1978 Jun 1;147(6):1713–1726. doi: 10.1084/jem.147.6.1713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed] [Google Scholar]
  23. STECK T. L., HOELZLWALLACH D. F. THE BINDING OF KIDNEY-BEAN PHYTOHEMAGGLUTININ BY EHRLICH ASCITES CARCINOMA. Biochim Biophys Acta. 1965 Mar 8;97:510–522. [PubMed] [Google Scholar]
  24. Shuman M. A., Majerus P. W. The perturbation of thrombin binding to human platelets by anions. J Clin Invest. 1975 Oct;56(4):945–950. doi: 10.1172/JCI108174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tollefsen D. M., Feagler J. R., Majerus P. W. The binding of thrombin to the surface of human platelets. J Biol Chem. 1974 Apr 25;249(8):2646–2651. [PubMed] [Google Scholar]
  26. Tollefsen D. M., Majerus P. W. Evidence for a single class of thrombin-binding sites of human platelets. Biochemistry. 1976 May 18;15(10):2144–2149. doi: 10.1021/bi00655a018. [DOI] [PubMed] [Google Scholar]
  27. Vogt W., Dieminger L., Lynen R., Schmidt G. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement. Hoppe Seylers Z Physiol Chem. 1974 Feb;355(2):171–183. doi: 10.1515/bchm2.1974.355.1.171. [DOI] [PubMed] [Google Scholar]
  28. Volanakis J. E., Schrohenloher R. E., Stroud R. M. Human factor D of the alternative complement pathway: purification and characterization. J Immunol. 1977 Jul;119(1):337–342. [PubMed] [Google Scholar]
  29. WROBLEWSKI F., LADUE J. S. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med. 1955 Oct;90(1):210–213. doi: 10.3181/00379727-90-21985. [DOI] [PubMed] [Google Scholar]
  30. Weksler B. B., Coupal C. E. Platelet-dependent generation of chemotactic activity in serum. J Exp Med. 1973 Jun 1;137(6):1419–1430. doi: 10.1084/jem.137.6.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Workman E. F., Jr, White G. C., 2nd, Lundblad R. L. Structure-function relationships in the interaction of alpha-thrombin with blood platelets. J Biol Chem. 1977 Oct 25;252(20):7118–7123. [PubMed] [Google Scholar]
  32. Zimmerman T. S., Kolb W. P. Human platelet-initiated formation and uptake of the C5-9 complex of human complement. J Clin Invest. 1976 Jan;57(1):203–211. doi: 10.1172/JCI108261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zucker M. B., Grant R. A. Aggregation and release reaction induced in human blood platelets by zymosan. J Immunol. 1974 Mar;112(3):1219–1230. [PubMed] [Google Scholar]
  34. Zucker M. B., Grant R. A., Alper C. A., Goodkofsky I., Lepow I. H. Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets. J Immunol. 1974 Dec;113(6):1744–1751. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES